Axiom Investors LLC DE Sells 7,903 Shares of Lantheus Holdings, Inc. $LNTH

Key Points

• Axiom Investors LLC DE decreased its stake in Lantheus Holdings by 8.2%, selling 7,903 shares and owning 88,947 shares valued at approximately $8.68 million.
• Insiders sold a total of 6,812,000 shares worth about $382.43 million in the last quarter, representing significant actions by company insiders.
• Lantheus reported an earnings miss for the last quarter, with earnings per share of $1.57, falling short of estimates and marking a 4.1% revenue decline year-over-year.

Axiom Investors LLC DE reduced its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 8.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 88,947 shares of the medical equipment provider's stock after selling 7,903 shares during the quarter. Axiom Investors LLC DE owned 0.13% of Lantheus worth $8,681,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. United Services Automobile Association bought a new position in shares of Lantheus in the first quarter valued at about $445,000. Ashton Thomas Private Wealth LLC raised its position in shares of Lantheus by 155.7% in the first quarter. Ashton Thomas Private Wealth LLC now owns 7,174 shares of the medical equipment provider's stock valued at $700,000 after purchasing an additional 4,368 shares during the period. Select Equity Group L.P. raised its position in shares of Lantheus by 899.2% in the first quarter. Select Equity Group L.P. now owns 100,843 shares of the medical equipment provider's stock valued at $9,842,000 after purchasing an additional 90,751 shares during the period. Polar Asset Management Partners Inc. bought a new position in shares of Lantheus in the first quarter valued at about $3,384,000. Finally, Nitorum Capital L.P. bought a new position in shares of Lantheus in the first quarter valued at about $23,261,000. 99.06% of the stock is owned by institutional investors.

Insider Activity at Lantheus

In related news, insider Farallon Partners L. L C/Ca sold 3,365,000 shares of the stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the sale, the insider owned 3,477,227 shares in the company, valued at approximately $195,246,296.05. This trade represents a 49.18% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Rajiv A. Patel sold 3,365,000 shares of the stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the sale, the insider owned 3,477,227 shares in the company, valued at $195,246,296.05. This represents a 49.18% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 6,812,000 shares of company stock worth $382,427,380 in the last quarter. 2.00% of the stock is currently owned by company insiders.

Lantheus Stock Performance

Shares of Lantheus stock opened at $54.75 on Monday. The company has a current ratio of 4.29, a quick ratio of 4.07 and a debt-to-equity ratio of 0.49. The company has a market cap of $3.72 billion, a PE ratio of 14.56 and a beta of 0.15. The company has a 50 day moving average of $66.59 and a 200-day moving average of $82.27. Lantheus Holdings, Inc. has a 1-year low of $47.25 and a 1-year high of $118.21.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.08). The firm had revenue of $378.05 million for the quarter, compared to analyst estimates of $389.69 million. Lantheus had a return on equity of 34.06% and a net margin of 17.82%.The business's revenue was down 4.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.80 EPS. As a group, equities research analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. B. Riley dropped their price objective on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating on the stock in a research report on Monday, June 23rd. JMP Securities decreased their price target on shares of Lantheus from $112.00 to $73.00 and set a "market outperform" rating on the stock in a research note on Thursday, August 7th. William Blair restated a "market perform" rating on shares of Lantheus in a research note on Wednesday, July 16th. Truist Financial set a $63.00 price target on shares of Lantheus and gave the company a "hold" rating in a research note on Monday, August 11th. Finally, Mizuho decreased their price target on shares of Lantheus from $120.00 to $70.00 and set an "outperform" rating on the stock in a research note on Thursday, August 7th. Four investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $91.60.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.